Matrix Metalloproteinase Expressions Play Important role in Prediction of Ovarian Cancer Outcome

Shujie Wang, Jia Jia, Dongyan Liu, Meng Wang, Zhen Wang, Xueling Li, Hongzhi Wang, Yong Rui, Zhirong Liu, Wei Guo, Jinfu Nie, Haiming DaiScientific 2019 · DOI

Abstract

Ovarian cancer remains a leading cause of cancer-related death due to late-stage diagnosis and chemoresistance. While Matrix Metalloproteinases (MMPs) are known to influence tumor progression, their specific roles in Ovarian Serous Cystadenocarcinoma (OSC) have been inconsistent across studies. This research systematically evaluates the MMP family using TCGA data and in vitro models. We identify MMP-19 and MMP-20 as independent predictors of poor overall survival. Functional assays demonstrate that these enzymes actively contribute to tumor invasion and resistance against clinical chemotherapy agents, suggesting they are viable therapeutic targets.

Introduction: The "Silent Killer" and the MMP Paradox

Ovarian cancer is frequently diagnosed at advanced stages, earning it the moniker "silent killer." Matrix Metalloproteinases (MMPs) are enzymes that degrade the extracellular matrix, traditionally associated with cancer invasion and metastasis. However, some studies suggest MMPs might have protective roles in certain contexts. To resolve this, researchers performed a comprehensive analysis of the MMP family in OSC to distinguish between "bystander" markers and active drivers of disease.

Methods: A Dual-Track Investigation

The study combined large-scale bioinformatics with laboratory validation. Researchers analyzed RNA-Seq and clinical data from 293 OSC patients in The Cancer Genome Atlas (TCGA). Statistical tools identified expression patterns across the entire MMP family to identify candidates for further study.

Heatmap and hierarchical clustering of MMP expression profiles in Ovarian Serous Cystadenocarcinoma (OSC) patients from the TCGA dataset.

To move beyond correlation, six ovarian cancer cell lines (including Ovcar8 and Cov362) were used to test the effects of MMP-19 and -20 silencing via siRNA. Researchers measured changes in drug sensitivity and invasive potential using flow cytometry and Transwell assays.

Key Insights: Beyond Simple Biomarkers

The analysis revealed that MMP-19 and -20 are not just markers of tumor stage; they are independent predictors of survival. High expression of these enzymes correlates with significantly poorer outcomes, regardless of the tumor's clinical grade. Furthermore, the study identified strong co-regulation patterns among MMPs, suggesting they may be part of a coordinated invasive program rather than isolated actors.

Key Results: Invasion and Resistance

  • Prognostic Power: In multivariate models, MMP-19 and MMP-20 were confirmed as independent risk factors for mortality, providing unique prognostic information beyond standard clinical staging.
  • Invasive Drive: Silencing MMP-19 or -20 significantly reduced the invasive capacity of cancer cells by up to 74% in certain cell lines.
  • Chemosensitization: High baseline levels of these MMPs were linked to drug resistance. Knocking them down sensitized cells to treatments like Carboplatin and the MCL1 inhibitor A-1210477.
Differential sensitivity of ovarian cancer cell lines (Ovcar8 and Cov362) to the MCL1 inhibitor A-1210477, illustrating the link between molecular profiles and drug resistance.

Conclusion and Future Directions

This study clarifies the role of MMPs in ovarian cancer, pinpointing MMP-19 and -20 as key players in both metastasis and chemoresistance. These results suggest these enzymes also influence apoptotic signaling pathways, not just physical matrix degradation. Future research should focus on the specific molecular mechanisms by which these MMPs confer resistance and explore the potential for targeted inhibitors in clinical settings.

Summary updated

Abstract

Ovarian cancer has a high death rate and is often not detected until late stages. While some studies found high expressions of MMPs correlated with cancer invasion, metastasis, and poor prognosis, however, several other studies indicated MMPs might inhibit cancer rather than promote cancer in certain situations. Thus, the role of different MMPs in different cancer types needs a systematic re-evaluation. In this study, we used RNA-Seq and corresponding clinical data downloaded from TCGA and analyzed the correlations between MMP expressions and the clinicopathologic characteristics and outcome in ovarian serous cystadenocarcinoma (OSC) patients. Among the MMPs investigated, MMP-3 was significantly increased in high-grade and high-stage tumors compared with low-grade and low-stage ones. Using univariate analysis and multivariate Cox model, high expressions of MMP-19 and -20 were found to associate with poor overall survival independent of clinicopathologic characteristics. Moreover, using in vitro studies, we found ovarian cancer cell lines with higher MMP-19 and -20 protein expressing levels were associated with anti-cancer drugs resistance, while knockdown of MMP-19 or -20 increased ovarian cancer cell sensitivities to several clinical using chemotherapy agents. Finally, knockdown of MMP-19 or -20 also decreased the invasion abilities of several ovarian cancer cell lines. These in vitro studies provided potential mechanisms of high MMP-19 and -20 expressions in the poor prognosis of ovarian cancer.
BibTeX
@inproceedings{wang2019matrix,
  author = {Shujie Wang and Jia Jia and Dongyan Liu and Meng Wang and Zhen Wang and Xueling Li and Hongzhi Wang and Yong Rui and Zhirong Liu and Wei Guo and Jinfu Nie and Haiming Dai},
  title = {{Matrix Metalloproteinase Expressions Play Important role in Prediction of Ovarian Cancer Outcome}},
  booktitle = {Scientific},
  year = {2019},
  doi = {10.1038/s41598-019-47871-5},
}
Figure